Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3568388 | 1.00 | NR1H2 (0.48) | NR1H2HPGDJAK2JAK1KDM4E | |
| SCHEMBL1996182 | 1.00 | NR1H2 (0.48) | NR1H2HPGDJAK2JAK1KDM4E | |
| SCHEMBL1401229 | 0.93 | MEN1 (0.52) | NR1H2HPGDJAK2JAK1MEN1 | |
| SCHEMBL20520884 | 0.93 | MEN1 (0.52) | NR1H2HPGDJAK2JAK1MEN1 | |
| SCHEMBL34473889 | 0.93 | MEN1 (0.52) | NR1H2HPGDJAK2JAK1MEN1 | |
| SCHEMBL1401260 | 0.90 | HPGD (0.53) | NR1H2HPGDKDM4EPKMMAPT | |
| SCHEMBL3071386 | 0.89 | NR1H2 (0.55) | NR1H2HPGDJAK2JAK1KDM4E | |
| SCHEMBL30228202 | 0.88 | GPR119 (0.45) | NR1H2HPGDJAK2JAK1KDM4E | |
| SCHEMBL24033042 | 0.87 | NR1H2 (0.43) | NR1H2HPGDJAK2JAK1KDM4E | |
| SCHEMBL34473790 | 0.87 | NR1H2 (0.43) | NR1H2HPGDJAK2JAK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-20230293535-A1 | ERBB/BTK INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20210252005-A1 | ERBB/BTK INHIBITORS | DIZAL (SHANGHAI) PHARMACEUTICAL CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| US-11007198-B2 | ErbB/BTK inhibitors | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-05-18 | — | — | US | disclosed |
| US-20200316079-A1 | ERBB/BTK INHIBITORS | DIZAL (SHANGHAI) PHARMACEUTICAL CO., LTD. (CN) | 2020-10-08 | — | — | US | disclosed |
| EP-3299358-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2018-03-28 | — | — | EP | disclosed |
| EP-1702917-B1 | AMIDE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-7728131-B2 | 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, having excellent tyrosine kinase inhibitory activity, used as therapeutic agent for leukemia | NIPPON SHINYAKU CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080293940-A1 | Amide Derivative and Medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2008-11-27 | — | — | US | disclosed |
| EP-1702917-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252005-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | NR1H2 2110/4885HPGD 3758/4885JAK2 13/4885 |
| US-11007198-B2 | ErbB/BTK inhibitors | ERBB2, BTK, ERBB3 | NR1H2 2110/4885HPGD 3758/4885JAK2 13/4885 |
| US-20200316079-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | NR1H2 2110/4885HPGD 3758/4885JAK2 13/4885 |
| US-20080293940-A1 | Amide Derivative and Medicine | ABL2, ABL1, BCR | NR1H2 853/4885HPGD 994/4885JAK2 4/4885 |
| US-20230293535-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | NR1H2 2110/4885HPGD 3758/4885JAK2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.